Effects of α1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6840-6846

  Sparreboom, Alex ^a   Chen, Huachen ^a   Acharya, Milin R ^a   Senderowicz, Adrian M ^a   Messmann, Richard A ^a   Kuwabara, Takashi ^b   Venzon, David J ^a   Murgo, Anthony J ^a   Headlee, Donna ^a   Sausville, Edward A ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; OROSOMUCOID; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; STAUROSPORINE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG PROTEIN BINDING; FEMALE; HUMAN; LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; OROSOMUCOID; STAUROSPORINE;

EID: 6044220124     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0805     Document Type: Article

References (26)

1. Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 2003;6:15-26.
2. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003;375:255-62.
3. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003;2:S84-95.
4. Sausville EA. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Curr Med Chem Anti-Canc Agents 2003;3:47-56.
5. Yasoshima K, Kuwabara T, Fuse E, et al. Pharmacokinetics, distribution, metabolism and excretion of. Cancer Chemother Pharmacol 2001;47:106-12.
6. Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha 1-acid glycoprotein. Cancer Res 1998;58:3248-53.
7. Kruger EA, Figg WD. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clin Cancer Res 2001;7:1867-72.
8. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33.
9. Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 2000; 14:338-43.
10. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alphal-acid glycoprotein in humans. Cancer Res 1999; 59:1054-60.
11. Sparreboom A, Nooter K, Loos WJ, Verweij J. The (ir)relevance of plasma protein binding of anticancer drugs. Neth J Med 2001;59:196-207.
12. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33:161-235.
13. Fuse E, Hashimoto A, Sato N, et al. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Pharm Res 2000;17:553-64.
14. Hedaya MA, Daoud SS. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. Anticancer Res 2001;21:4005-10.
15. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74:364-71.
16. Sparreboom A, Wolff AC, Verweij J, et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res 2003;9:151-9.
17. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625-32.
18. Kurata N, Kuwabara T, Tanii H, et al. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother Pharmacol 1999;44:12-8.
19. Haroldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother 2000;34:183-87.
20. Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991;20:429-46.
21. Jackson PR, Tucker GT, Woods HF. Altered plasma drug binding in cancer, role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther 1982;32:295-302.
22. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988;40:1-47.
23. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-8.
24. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002;38: 1677-84.
25. Wolner E, Domanig E Jr., Elkadi A, Helmer F, Romer P. [On a simple relation between blood volume and body surface area]. Z Kreislaufforsch 1968;57:79-84.
26. Bailey BJ, Briars GL. Estimating the surface area of the human body. Stat Med 1996;15:1325-32.